Background. Reduced cardiac vagal tone in patients with myocardial infarction (MI) is associated with a high risk of sudden death. Muscarinic blocking agents in small doses induce a paradoxical increase in cardiac vagal activity in normal subjects. We tested whether low doses of scopolamine delivered transdermally enhance tonic and reflex cardiac vagal activity in patients in the acute phase of MI.
Methods and Results. Patients were randomized to a scopolamine (n=17) or a placebo patch (n= 19) in a double-blind fashion 4.20±0.18 days after acute MI. Cardiac vagal activity was assessed by testing the arterial baroreflex sensitivity (BRS) using the phenylephrine method and by power spectral analysis of the RR interval variability. Twenty-four hours after scopolamine, we found a significant increase in BRS (from 7.05±+1.21 to 13.99±2.33 ms/mm Hg, P<.05) and in RR variability, expressed as the mean standard deviation of 512 normal consecutive RR intervals (from 18.09±2.64 to 31.16±4.16 milliseconds, P<.05). The amplitude of respiratory sinus arrhythmia, measured by the absolute power of the high-frequency spectral component, was also enhanced (from 62.55+21.49 to 305.33 ±95.68 milliseconds squared, P<.05), whereas the power in the low-frequency spectral component of the RR variability, which results from the interaction between cardiac sympathetic and vagal activity, did not change significantly ( Two main peaks in the spectra of the RR variability were identified: a high-frequency (HF) peak (centered at about 0.30 Hz in our patients), which corresponds to respiratory sinus arrhythmia17 and reflects the cardiac vagal activity, and a low-frequency (LF) peak centered at about 0.1 Hz, which can be mediated by both sympathetic and vagal outflow to the heart. [17] [18] [19] [20] Baroreflex Sensitivity
After the ECG recording for spectral analysis, baroreflex sensitivity (BRS) was assessed by the phenylephrine ramp method.21 Beat-to-beat blood pressure (BP) recordings were obtained noninvasively from the finger by an infrared photoplethysmograph (2300 Finapres BP Monitor, Ohmeda, Englewood, Colo). The accuracy of this instrument in measuring BP changes induced by injections of vasoactive drugs has been validated previously.22
All patients received four to six rapid intravenous injections of phenylephrine HCl at 3-minute intervals. The initial dose of 0.1 mg was adjusted to obtain an increase between 20 and 30 mm Hg in systolic blood pressure (SBP). The test was then repeated until at least three recordings were made with the optimum phenylephrine dose. The sensitivity of the baroreflex, expressed in milliseconds per millimeter of mercury, was obtained from the average slope of at least three regression lines relating beat-to-beat change in RR interval to the change in the preceding SBP, as described by Smyth et al. 21 Only regression lines that had a correlation coefficient >0.80 were used. All measurements were made before and 24 hours after application of a patch (of scopolamine or placebo) behind the ear. Differences between treatments were assessed by twofactor (time and treatment) ANOVA. Significance was established at probability values <.05. Data are given mean±SEM.
Results
There were no statistical differences in the characteristics of the patients in the two treatment groups (Table  1) . Only data from patients who were uncomplicated and on a stable drug regime (ie, last new treatment started at least 3 days before the beginning of the study) were included in the results (see "Methods"). Scopolamine was well tolerated: Only two patients complained of dry mouth, and no other side effects were seen.
The mean value of BRS was almost doubled by low doses of scopolamine (from 7.05±1.21 to 13.99±+2.33 ms/mm Hg, P<.05) ( Table 2 ). As shown in Fig 1, BRS increased in all except one of the patients. In that patient, scopolamine also decreased RR interval, suggesting that the peripheral muscarinic receptor blockade predominated over the paradoxical vagomimetic effect.
The results of the spectral analysis of the RR variability for the two treatments are summarized in Table  2 . The standard deviation of the RR (ie, the square root of the total spectral power) was significantly higher after scopolamine (P<.05). The absolute power of the HF component increased with scopolamine (P<.05), whereas the LF power did not change significantly (P=.93). This indicates that the increase in the amplitude of the respiratory sinus arrhythmia, and hence, in cardiac vagal tone, was mainly responsible for the rise in RR variability. Low doses of scopolamine also increased the average RR interval, but this was not statistically significant (P=.24). Table  2 , HFc did not change (P=.64) in either group of patients after scopolamine or placebo.
There is no evidence to suggest that the paradoxical increase in BRS and RR variability observed with low doses of antimuscarinics results from a direct inhibition of cardiac sympathetic activity.24 However, it is known that the two limbs of the autonomic nervous system interact at the presynaptic level by modulating the release of the respective neurotransmitters.25 It is therefore possible that increased concentrations of acetylcholine in the synaptic cleft induced by scopolamine could inhibit the release of norepinephrine from the sympathetic nerve terminals.26 To test for a possible role of the sympathetic nervous system in the paradoxical effect of low doses of scopolamine, we have separately analyzed the subgroup of patients on p-blockers (,pB+). As expected, measurements at baseline in the fBB+ patients differed from those in the control group (,BB-) (Table 3) Placebo not different in the two subgroups. Although this analysis is limited by the small sample size and the differences between the patients in the two subgroups, the results further suggest that the effect of low doses of scopolamine is mediated by the vagus. Discussion Our results have confirmed that low doses of scopolamine, delivered transdermally, can induce a sustained increase in BRS and RR variability. We have also demonstrated that the rise in RR variability was mainly due to an increase in the amplitude of the respiratory sinus arrhythmia. This supports the hypothesis that a rise in cardiac vagal outflow is the mechanism underlying the paradoxical effect of low doses of scopolamine. Furthermore, the present study has shown that a sustained pharmacological stimulation of cardiac vagal tone is attainable in patients in the acute phase of MI. These findings may have important therapeutic implications for two reasons. First, in patients after MI, there is a strong relation between autonomic balance and mortality. High sympathetic activity and low vagal outflow, indicated by low BRS,4 reduced respiratory sinus arrhythmia,1 and RR variability,2. recently have suggested that synaptic acetylcholine could inhibit its own release through the activation of the M1 presynaptic receptors. Since atropine has a relatively higher affinity for the M1-subtype receptors, in low concentrations it would preferentially bind to them, leaving the postsynaptic M2-subtype receptors relatively unaffected. This would result in a greater release of acetylcholine for any given level of neural activation and hence in a higher postsynaptic vagal outflow. Importantly, these investigators also ruled out a possible role of the ,3-adrenergic system in mediating the atropine-induced bradycardia. Although our study could not completely exclude a possible interaction between scopolamine and /BB+, the results suggest that the paradoxical effects of scopolamine are mediated by the vagus (Table 3) .
Unfortunately, the design of the present study did not allow us to investigate the effect of low doses of scopolamine on 24-hour RR variability, which is undoubtedly the best-validated prognostic indicator in this group of patients. However, our preliminary data from a controlled cross-over study in patients with chronic heart failure of ischemic etiology show a substantial increase in both 24-hour RR interval and its variability with transdermal scopolamine.33
In summary, we have shown that low doses of scopolamine cause a sustained increase in cardiac vagal tone and improve the autonomic indices associated with a high mortality in patients in the acute phase of MI. This suggests that pharmacological vagal stimulation may have important therapeutic potential in preventing sudden death in patients after MI. However, previous studies have shown that reversing the prognostic indicators of sudden death does not necessarily result in a decrease in fatal arrhythmias.34 Although experimental evidence from animal models of sudden death strongly suggests that vagal stimulation is effective and safe,6,28,29 large trials are needed to assess the validity of this treatment in humans. Likewise, we have no information concerning the tolerability and efficacy of transdermal scopolamine on long-term treatment. There is no clear evidence of a greater incidence of side effects when transdermal scopolamine is administered for a week35; however, whether the paradoxical vagomimetic effect of scopolamine would be maintained on chronic administration remains to be assessed.
